Atlas Trials

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

Clinical trial NCT01259063 · COMPLETED

Trial details

NCT number
NCT01259063
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2010-12-01
Primary completion
2017-06-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.